Amgen, Horizon Deal Faces Off With FTC
Bloomberg Businessweek
00:00
The Balance Between Competition and Innovation
There's a debate about whether there is enough competition to spur innovation. Some economists have done studies showing that the rate of innovation has slowed down, particularly in pharma and tech in the United States. Jim Boulden: I'm just thinking about, you know, the innovation that spurred the mRNA vaccines didn't come from big pharma. That came from smaller players.
Play episode from 08:57
Transcript
